Skip to main content

ESTUDIO ALEATORIZADO Y DOBLE-CIEGO PARA VALORAR EL BENEFICIO DEL TRATAMIENTO CON COLCHICINA EN PACIENTES CON IC AGUDA (COLICA)

ICI19/00055

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación Clínica Independiente
Call year 2019
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION PARA LA FORMACION E INVESTIGACION SANITARIAS DE LA REGION DE MURCIA (FFIS)
Execution centre INSTITUTO MURCIANO DE INVESTIGACION BIOSANITARIA (IMIB)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Colchicine in acutely decompensated heart failure, the COLICA trial

  • Pascual-Figal, DA.|||0000-0002-4993-9540
  • Núñez, Julio|||0000-0003-1672-7119
  • Pérez-Martínez, Maria T.|||0000-0003-1053-7066
  • González Juanatey, José Ramón|||0000-0001-9681-3388
  • Taibo-Urquia, Mikel|||0000-0003-2404-3657
  • Llàcer-Iborra, Pau|||0000-0002-0988-0599
  • Delgado-Jiménez, Juan Francisco|||0000-0002-5401-8324
  • Villar, Sandra|||0000-0001-8229-6279
  • Mirabet Pérez, Sonia|||0000-0001-5955-2748
  • Aimo, Alberto|||0000-0001-9129-9519
  • Riquelme Pérez, Alejandro
  • Anguita-Sánchez, Manuel|||0000-0001-7875-7263
  • Martínez-Sellés, Manuel|||0000-0003-0289-6229
  • Noguera-Velasco, José A.|||0000-0001-6786-4864
  • Ibañez, Borja|||0000-0002-5036-254X
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
Background and Aims Acute heart failure (AHF) promotes inflammatory activation, which is associated with worse outcomes. Colchicine has proven effective in other cardiovascular conditions characterized by inflammatory activation, but has never been evaluated in the setting of AHF. Methods This multicenter, randomized, double-blind, and placebo-controlled trial included patients with AHF, requiring ≥40 mg of intravenous furosemide, regardless of their left ventricular ejection fraction (LVEF) and inpatient or outpatient setting. Patients were randomized within the first 24 h of presentation to receive either colchicine or placebo, with loading dose of 2 mg, followed by 0.5 mg every 12 h for 8 weeks. Results A total of 278 patients [median age 75 years, LVEF 40%, baseline N-terminal pro-B-type natriuretic peptide (NT-proBNP) 4262 pg/mL] were randomized to colchicine (n = 141) or placebo (n = 137). The primary endpoint, the time-averaged reduction in NT-proBNP levels at 8 weeks, did not differ between the colchicine group [-62.2%, 95% confidence interval (CI) -68.9% to -54.2%] and the placebo group (-62.1%, 95% CI -68.6% to -54.3%) (ratio of change 1.0). The reduction in inflammatory markers was significantly greater with colchicine: ratio of change 0.60 (P <.001) for C-reactive protein and 0.72 (P =.019) for interleukin-6. No differences were found in new worsening heart failure episodes (14.9% with colchicine vs. 16.8% with placebo, P =.698); however, the need for intravenous furosemide during follow-up was lower with colchicine (P =.043). Diarrhea was slightly more common with colchicine, but it did not result in differences in medication withdrawal (8.5% vs. 8.8%). Conclusions Colchicine was safe and effective in reducing inflammation in patients with AHF; however, colchicine and placebo exhibited comparable effects on reducing NT-proBNP and preventing new worsening heart failure events.